Dr. Ryan Matthew Rhome, MD, PhD

Dr. Rhome practices at Advocate Illinois Masonic Medical Center in Chicago, Illinois, part of Advocate Health.

Dr. Rhome's NPI, 1023370400, was assigned on June 12, 2012. Dr. Rhome graduated from Medical University of South Carolina College of Medicine in 2012. Dr. Rhome holds New York license 036167537.

Dr. Rhome's primary practice is Advocate Illinois Masonic Medical Center, at 836 West Wellington Avenue, Chicago, IL 60657 in Cook County. The practice phone is (773) 975-1600.

Dr. Rhome's primary practice is Advocate Illinois Masonic Medical Center in Chicago, Illinois, part of Advocate Health. Dr. Rhome is also affiliated with Advocate Lutheran General Hospital. The medical group on file is Radiation Oncology Consultants. Dmand AI also links Dr. Rhome to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rhome practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Rhome's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Rhome is licensed in New York.

CMS data shows 792 Medicare services from Dr. Rhome across 13 procedure codes in 2024, for 167 Medicare patients. Medicare paid $55,115 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 167 Medicare patients who saw Dr. Rhome in 2024. The largest group is 65 to 74, with 84 patients. 75% of them have cancer, and 75% have high blood pressure. 25% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rhome's median patient age at 67, with 60% women.

In 2024, Dr. Rhome wrote 80 Medicare Part D claims for 39 patients. 95% of them were for generic drugs. CMS names the drug for 52 of them, across 3 drugs with 11 or more claims each, at $489 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 72 out of 100 for Dr. Rhome for performance year 2024, reported as part of a group. Dr. Rhome accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 28 papers to Dr. Rhome, published from 2011 to 2023. 2017 was the busiest year, with 4. The most frequent topics are Adenocarcinoma, Breast Neoplasms and Carcinoma, Squamous Cell. Dr. Rhome has published most often in Adv Radiat Oncol. Dr. Rhome's most frequent co-authors are Richard C. Zellars, MD, Namita Agrawal, MD and Kevin Ren-Yeh Shiue, MD.

Dmand AI links Dr. Rhome to 1 clinical trial. Conditions studied include Brain Neoplasms and Central Nervous System Neoplasms.

CMS Open Payments shows 4 general payments to Dr. Rhome from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Teleflex LLC paid the most, $155.

Dr. Rhome graduated from Medical University of South Carolina College of Medicine in 2012.